Liminal BioSciences Inc., a development-stage biopharmaceutical company, has terminated the long-term legacy Master Services Agreement that it entered into in May 2015 as amended, relating to its previously owned plasma-derived therapeutics business.   The company had previously sent an early five-year termination notice to terminate the CDMO Agreement in August 2021. The CDMO Agreement included a minimum purchase commitment of $9 million per year for the remainder of the contract.   This te...